Principal Financial Group
MDGL icon

Principal Financial Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Principal Financial Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,239
Closed -$649K – 2222
2026
Q1 		$649K Sell
1,239
-6,022
-83% -$2.88M ﹤0.01% 2003
2025
Q4 		$4.23M Sell
7,261
-4,807
-40% -$2.46M ﹤0.01% 1668
2025
Q3 		$5.54M Buy
12,068
+2,862
+31% +$1.07M ﹤0.01% 1552
2025
Q2 		$2.79M Buy
9,206
+7,772
+542% +$2.32M ﹤0.01% 1740
2025
Q1 		$475K Sell
1,434
-96
-6% -$31.5K ﹤0.01% 1940
2024
Q4 		$472K Sell
1,530
-96
-6% -$27K ﹤0.01% 1975
2024
Q3 		$345K Sell
1,626
-1,430
-47% -$366K ﹤0.01% 2009
2024
Q2 		$856K Sell
3,056
-946
-24% -$225K ﹤0.01% 1876
2024
Q1 		$1.07M Buy
4,002
+127
+3% +$29.9K ﹤0.01% 1860
2023
Q4 		$897K Buy
3,875
+142
+4% +$24.8K ﹤0.01% 1855
2023
Q3 		$545K Sell
3,733
-78
-2% -$14.7K ﹤0.01% 1930
2023
Q2 		$880K Sell
3,811
-119
-3% -$32.2K ﹤0.01% 1860
2023
Q1 		$952K Sell
3,930
-267
-6% -$72.8K ﹤0.01% 1859
2022
Q4 		$1.22M Buy
4,197
+366
+10% +$35.8K ﹤0.01% 1832
2022
Q3 		$249K Sell
3,831
-65
-2% -$4.52K ﹤0.01% 2144
2022
Q2 		$279K Buy
3,896
+1,758
+82% +$129K ﹤0.01% 2205
2022
Q1 		$210K Buy
+2,138
New +$180K ﹤0.01% 2327
2021
Q4 		– Sell
-3,184
Closed -$254K – 2592
2021
Q3 		$254K Sell
3,184
-515
-14% -$44.5K ﹤0.01% 2357
2021
Q2 		$360K Sell
3,699
-1,647
-31% -$195K ﹤0.01% 2297
2021
Q1 		$625K Sell
5,346
-61
-1% -$7.11K ﹤0.01% 2098
2020
Q4 		$601K Buy
5,407
+2,181
+68% +$267K ﹤0.01% 2071
2020
Q3 		$383K Sell
3,226
-156
-5% -$16.9K ﹤0.01% 2073
2020
Q2 		$383K Buy
+3,382
New +$333K ﹤0.01% 2034
2020
Q1 		– Sell
-2,320
Closed -$211K – 2231
2019
Q4 		$211K Buy
+2,320
New +$225K ﹤0.01% 2128
2019
Q3 		– Sell
-2,254
Closed -$236K – 2258
2019
Q2 		$236K Buy
2,254
+35
+2% +$3.75K ﹤0.01% 2115
2019
Q1 		$278K Buy
2,219
+177
+9% +$22K ﹤0.01% 2056
2018
Q4 		$230K Sell
2,042
-7,263
-78% -$1.12M ﹤0.01% 2097
2018
Q3 		$1.99M Buy
9,305
+556
+6% +$140K ﹤0.01% 1760
2018
Q2 		$2.45M Buy
+8,749
New +$1.54M ﹤0.01% 1735
2016
Q2 		– Sell
-439
Closed -$4K – 2191
2016
Q1 		$4K Hold
439
– – ﹤0.01% 2173
2015
Q4 		$5K Hold
439
– – ﹤0.01% 2190
2015
Q3 		$27K Sell
439
-269
-38% -$19.4K ﹤0.01% 2171
2015
Q2 		$55K Buy
708
+174
+33% +$14.6K ﹤0.01% 2167
2015
Q1 		$36K Sell
534
-6
-1% -$515 ﹤0.01% 2142
2014
Q4 		$50K Buy
+540
New +$55.8K ﹤0.01% 2150
2013
Q3 		– Sell
-625
Closed -$109K – 2282
2013
Q2 		$109K Buy
+625
New +$163K ﹤0.01% 2192

Other funds holding MDGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EAM
EULAV Asset Management Sarasota, Florida $3.13B AUM 23.04% 1-Year Est. Return

Principal Financial Group's MDGL Position: Q2 2026 in Review

Principal Financial Group sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 1,239 shares — an estimated $649K sold.

Principal Financial Group first reported a position in MDGL in Q2 2013 and held it in 36 quarters. The position peaked at $5.54M in Q3 2025. 157 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Principal Financial Group reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Principal Financial Group sold 1,239 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $649K.
  • Principal Financial Group first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 36 quarters.
  • Principal Financial Group's Madrigal Pharmaceuticals position peaked at $5.54M in Q3 2025.
  • 157 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.